Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been given an average recommendation of “Moderate Buy” by the twelve brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $10.9091.

A number of equities analysts have issued reports on TSHA shares. Chardan Capital restated a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. Citizens Jmp set a $8.00 target price on Taysha Gene Therapies in a research note on Wednesday, November 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a research report on Friday, November 14th. Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Finally, The Goldman Sachs Group set a $11.00 target price on Taysha Gene Therapies in a research note on Thursday, December 4th.

Insiders Place Their Bets

In related news, insider Sukumar Nagendran sold 260,047 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97. Following the completion of the transaction, the insider directly owned 1,006,439 shares of the company’s stock, valued at $4,539,039.89. This represents a 20.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Sean P. Nolan sold 136,789 shares of the firm’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $649,747.75. Following the completion of the sale, the chief executive officer owned 2,949,569 shares of the company’s stock, valued at $14,010,452.75. This trade represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 968,795 shares of company stock worth $4,518,093. 3.78% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TSHA. AQR Capital Management LLC boosted its position in shares of Taysha Gene Therapies by 325.6% during the first quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock valued at $150,000 after purchasing an additional 82,545 shares in the last quarter. Ethic Inc. purchased a new position in Taysha Gene Therapies during the second quarter valued at $67,000. Tybourne Capital Management HK Ltd. boosted its holdings in shares of Taysha Gene Therapies by 10.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 4,095,000 shares of the company’s stock valued at $9,459,000 after buying an additional 395,000 shares in the last quarter. May Hill Capital LLC purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth about $37,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth about $186,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Up 3.0%

Shares of Taysha Gene Therapies stock opened at $4.84 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $6.02. The company’s 50 day moving average price is $5.00 and its 200-day moving average price is $4.35. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -14.67 and a beta of 1.01.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.